Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease(♦)(♦)This work was supported by grants from the Fondo Nacional de Ciencia y Tecnología de Chile (FONDECYT) #1110455 to M.A., #1100971 to M.A-L. and #1100020 to F.N.
Background. The plasminogen activator inhibitor type-1 (PAI-1) has been implicated in the regulation of fibrinolysis and extracellular matrix components. The single base pair guanine insertion/deletion polymorphism (4G/5G) within the promoter region of the PAI-1 gene influences PAI-1 synthesis and m...
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2011-10-01
|
Series: | Annals of Hepatology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268119315182 |
id |
doaj-2ae28f0dfd2d45569c44f46a637dbec9 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alberto Espino Andrea Villagrán Valeska Vollrath Paulina Hanckes Roberto Salas Andrea Farah Nancy Solís Margarita Pizarro Alex Escalona Camilo Boza Gustavo Pérez Gonzalo Carrasco Oslando Padilla Juan Francisco Miquel Flavio Nervi Norberto C. Chavez-Tapia Juan Pablo Arab Manuel Álvarez-Lobos Marco Arrese Arnoldo Riquelme |
spellingShingle |
Alberto Espino Andrea Villagrán Valeska Vollrath Paulina Hanckes Roberto Salas Andrea Farah Nancy Solís Margarita Pizarro Alex Escalona Camilo Boza Gustavo Pérez Gonzalo Carrasco Oslando Padilla Juan Francisco Miquel Flavio Nervi Norberto C. Chavez-Tapia Juan Pablo Arab Manuel Álvarez-Lobos Marco Arrese Arnoldo Riquelme Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease(♦)(♦)This work was supported by grants from the Fondo Nacional de Ciencia y Tecnología de Chile (FONDECYT) #1110455 to M.A., #1100971 to M.A-L. and #1100020 to F.N. Annals of Hepatology Plasminogen activator inhibitor type 1 Single nucleotide polymorphisms Liver fibrosis Non-alcoholic fatty liver disease Steatosis |
author_facet |
Alberto Espino Andrea Villagrán Valeska Vollrath Paulina Hanckes Roberto Salas Andrea Farah Nancy Solís Margarita Pizarro Alex Escalona Camilo Boza Gustavo Pérez Gonzalo Carrasco Oslando Padilla Juan Francisco Miquel Flavio Nervi Norberto C. Chavez-Tapia Juan Pablo Arab Manuel Álvarez-Lobos Marco Arrese Arnoldo Riquelme |
author_sort |
Alberto Espino |
title |
Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease(♦)(♦)This work was supported by grants from the Fondo Nacional de Ciencia y Tecnología de Chile (FONDECYT) #1110455 to M.A., #1100971 to M.A-L. and #1100020 to F.N. |
title_short |
Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease(♦)(♦)This work was supported by grants from the Fondo Nacional de Ciencia y Tecnología de Chile (FONDECYT) #1110455 to M.A., #1100971 to M.A-L. and #1100020 to F.N. |
title_full |
Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease(♦)(♦)This work was supported by grants from the Fondo Nacional de Ciencia y Tecnología de Chile (FONDECYT) #1110455 to M.A., #1100971 to M.A-L. and #1100020 to F.N. |
title_fullStr |
Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease(♦)(♦)This work was supported by grants from the Fondo Nacional de Ciencia y Tecnología de Chile (FONDECYT) #1110455 to M.A., #1100971 to M.A-L. and #1100020 to F.N. |
title_full_unstemmed |
Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease(♦)(♦)This work was supported by grants from the Fondo Nacional de Ciencia y Tecnología de Chile (FONDECYT) #1110455 to M.A., #1100971 to M.A-L. and #1100020 to F.N. |
title_sort |
plasminogen activator inhibitor type 1 serum levels and 4g/5g gene polymorphism in morbidly obese hispanic patients with non-alcoholic fatty liver disease(♦)(♦)this work was supported by grants from the fondo nacional de ciencia y tecnología de chile (fondecyt) #1110455 to m.a., #1100971 to m.a-l. and #1100020 to f.n. |
publisher |
Elsevier |
series |
Annals of Hepatology |
issn |
1665-2681 |
publishDate |
2011-10-01 |
description |
Background. The plasminogen activator inhibitor type-1 (PAI-1) has been implicated in the regulation of fibrinolysis and extracellular matrix components. The single base pair guanine insertion/deletion polymorphism (4G/5G) within the promoter region of the PAI-1 gene influences PAI-1 synthesis and may modulate hepatic fibrogenesis.Aim. To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients.Material and methods. Case-control study of 50 obese patients undergoing bariatric surgery and 71 non-obese subjects matched by age and sex. Anthropometric and biochemical measurements were performed, including PAI-1 serum levels. Genomic DNA was obtained to assess the presence of 4G/5G polymorphism.Results. BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects. PAI-1 serum levels observed in obese patients were significantly lower (10.63 ± 4.82) compared to controls (14.26 ± 11.4; p < 0.05). No differences were observed in the PAI-1 4G/5G promoter genotypes frequencies (p = 0.12). No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 ± 4.35) compared to patients without liver fibrosis (10.61 ± 5.2; p = 0.985). PAI-1 4G/5G promoter genotypes frequencies were similar in patients with or without liver fibrosis associated to NASH (p = 0.6).Conclusions. Morbidly obese patients had significantly lower PAI-1 serum levels with similar PAI-1 4G/5G genotypes frequencies compared to non-obese subjects. The frequency of 4G/5G genotypes in Chilean Hispanic healthy subjects was similar to that described in other populations. No association was found between PAI-1 serum levels or 4G/5G genotype with liver fi-brosis in obese patients. |
topic |
Plasminogen activator inhibitor type 1 Single nucleotide polymorphisms Liver fibrosis Non-alcoholic fatty liver disease Steatosis |
url |
http://www.sciencedirect.com/science/article/pii/S1665268119315182 |
work_keys_str_mv |
AT albertoespino plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT andreavillagran plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT valeskavollrath plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT paulinahanckes plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT robertosalas plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT andreafarah plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT nancysolis plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT margaritapizarro plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT alexescalona plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT camiloboza plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT gustavoperez plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT gonzalocarrasco plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT oslandopadilla plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT juanfranciscomiquel plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT flavionervi plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT norbertocchaveztapia plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT juanpabloarab plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT manuelalvarezlobos plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT marcoarrese plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn AT arnoldoriquelme plasminogenactivatorinhibitortype1serumlevelsand4g5ggenepolymorphisminmorbidlyobesehispanicpatientswithnonalcoholicfattyliverdiseasethisworkwassupportedbygrantsfromthefondonacionaldecienciaytecnologiadechilefondecyt1110455toma1100971tomaland1100020tofn |
_version_ |
1721388681449701376 |
spelling |
doaj-2ae28f0dfd2d45569c44f46a637dbec92021-06-09T05:55:00ZengElsevierAnnals of Hepatology1665-26812011-10-01104493501Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease(♦)(♦)This work was supported by grants from the Fondo Nacional de Ciencia y Tecnología de Chile (FONDECYT) #1110455 to M.A., #1100971 to M.A-L. and #1100020 to F.N.Alberto Espino0Andrea Villagrán1Valeska Vollrath2Paulina Hanckes3Roberto Salas4Andrea Farah5Nancy Solís6Margarita Pizarro7Alex Escalona8Camilo Boza9Gustavo Pérez10Gonzalo Carrasco11Oslando Padilla12Juan Francisco Miquel13Flavio Nervi14Norberto C. Chavez-Tapia15Juan Pablo Arab16Manuel Álvarez-Lobos17Marco Arrese18Arnoldo Riquelme19Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Cirugía Digestiva, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Cirugía Digestiva, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Cirugía Digestiva, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Patología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Salud Pública, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileMedica Sur Clinic and Foundation, Mexico City, MexicoDepartamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; Correspondence and reprint request:Background. The plasminogen activator inhibitor type-1 (PAI-1) has been implicated in the regulation of fibrinolysis and extracellular matrix components. The single base pair guanine insertion/deletion polymorphism (4G/5G) within the promoter region of the PAI-1 gene influences PAI-1 synthesis and may modulate hepatic fibrogenesis.Aim. To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients.Material and methods. Case-control study of 50 obese patients undergoing bariatric surgery and 71 non-obese subjects matched by age and sex. Anthropometric and biochemical measurements were performed, including PAI-1 serum levels. Genomic DNA was obtained to assess the presence of 4G/5G polymorphism.Results. BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects. PAI-1 serum levels observed in obese patients were significantly lower (10.63 ± 4.82) compared to controls (14.26 ± 11.4; p < 0.05). No differences were observed in the PAI-1 4G/5G promoter genotypes frequencies (p = 0.12). No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 ± 4.35) compared to patients without liver fibrosis (10.61 ± 5.2; p = 0.985). PAI-1 4G/5G promoter genotypes frequencies were similar in patients with or without liver fibrosis associated to NASH (p = 0.6).Conclusions. Morbidly obese patients had significantly lower PAI-1 serum levels with similar PAI-1 4G/5G genotypes frequencies compared to non-obese subjects. The frequency of 4G/5G genotypes in Chilean Hispanic healthy subjects was similar to that described in other populations. No association was found between PAI-1 serum levels or 4G/5G genotype with liver fi-brosis in obese patients.http://www.sciencedirect.com/science/article/pii/S1665268119315182Plasminogen activator inhibitor type 1Single nucleotide polymorphismsLiver fibrosisNon-alcoholic fatty liver diseaseSteatosis |